Related references
Note: Only part of the references are listed.Terminally Exhausted CD8± T Cells Resistant to PD-1 Blockade Promote Generation and Maintenance of Aggressive Cancer Stem Cells
Mohona Chakravarti et al.
CANCER RESEARCH (2023)
Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients - a case report
Valentin Coudert et al.
ACTA ONCOLOGICA (2021)
Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review
Xiaojie Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care
Simon Lennartz et al.
ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN (2020)
Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy
Daichi Fujimoto et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Curative effect assessment of immunotherapy for non-small cell lung cancer: The blind area of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
Peng Song et al.
THORACIC CANCER (2019)
Novel patterns of response under immunotherapy
E. Borcoman et al.
ANNALS OF ONCOLOGY (2019)
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor
Norikazu Matsuo et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases
Surabhi Ranjan et al.
BMC CANCER (2018)
The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients
Minglei Zhuo et al.
CANCER BIOMARKERS (2018)
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer
Alona Zer et al.
CLINICAL LUNG CANCER (2018)
Pseudoprogression and hyperprogression after checkpoint blockade
Qiaohong Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
CD103+CD8+Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC
Pedro Rocha et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report
Guihong Liu et al.
THORACIC CANCER (2018)
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies
Jenny H. Lee et al.
JAMA ONCOLOGY (2018)
Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma
Vishwajith Sridharan et al.
ORAL ONCOLOGY (2018)
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series
Masaki Kanazu et al.
THORACIC CANCER (2018)
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy
Martina Vrankar et al.
RADIOLOGY AND ONCOLOGY (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy
Maximilian J. Hochmair et al.
LUNG CANCER (2017)
Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review
Young Kwang Chae et al.
ONCOTARGET (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression
Junko Tanizaki et al.
LUNG CANCER (2016)
Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma
Shrujal S. Baxi et al.
ORAL ONCOLOGY (2016)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Share Paper
